NASDAQ:MRTX - Mirati Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$55.05 +4.05 (+7.94 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$55.05
Today's Range$50.90 - $58.2750
52-Week Range$4.45 - $58.28
Volume1.20 million shs
Average Volume460,314 shs
Market Capitalization$1.48 billion
P/E Ratio-19.80
Dividend YieldN/A
Beta2.15
Mirati Therapeutics logoMirati Therapeutics, Inc., a clinical-stage oncology company, develops targeted therapeutics to address the genetic, epigenetic, and immunological promoters of cancer. The company is involved in developing sitravatinib, an oral spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of solid tumor; and in Phase Ib clinical trial to treat non-small cell lung cancer (NCSLC) patients with CBL, chromosome 4q12, and RET genetic alterations, as well as mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor that is in Phase II clinical trial in combination with durvalumab for the treatment of patients with NSCLC. Its preclinical development stage product candidate include KRAS G12C inhibitor program to address mutations and tumors. The company has a collaboration and license agreement with BeiGene, Ltd. to develop manufacture and commercialize sitravatinib. It also has collaboration with Astex Pharmaceuticals, Inc. and Merck & Co., Inc.; and Array BioPharma, Inc. to develop and commercialize products. Mirati Therapeutics, Inc. is headquartered in San Diego, California.

Receive MRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for MRTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MRTX
CUSIPN/A
Phone858-332-3410

Debt

Debt-to-Equity RatioN/A
Current Ratio9.56
Quick Ratio9.56

Price-To-Earnings

Trailing P/E Ratio-19.80
Forward P/E Ratio-19.25
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$5.31 per share
Price / Book10.37

Profitability

EPS (Most Recent Fiscal Year)($2.78)
Net Income$-70,420,000.00
Net MarginsN/A
Return on Equity-62.28%
Return on Assets-55.07%

Miscellaneous

Employees51
Outstanding Shares29,050,000
Market Cap$1,481.66

Mirati Therapeutics (NASDAQ:MRTX) Frequently Asked Questions

What is Mirati Therapeutics' stock symbol?

Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."

How were Mirati Therapeutics' earnings last quarter?

Mirati Therapeutics Inc (NASDAQ:MRTX) announced its quarterly earnings data on Monday, May, 7th. The biotechnology company reported ($0.51) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.63) by $0.12. The biotechnology company had revenue of $9.47 million for the quarter, compared to analyst estimates of $10 million. View Mirati Therapeutics' Earnings History.

What price target have analysts set for MRTX?

10 equities research analysts have issued 1-year price targets for Mirati Therapeutics' shares. Their forecasts range from $5.00 to $64.00. On average, they anticipate Mirati Therapeutics' stock price to reach $43.00 in the next year. This suggests that the stock has a possible downside of 21.9%. View Analyst Ratings for Mirati Therapeutics.

What is the consensus analysts' recommendation for Mirati Therapeutics?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Mirati Therapeutics stock?

Here are some recent quotes from research analysts about Mirati Therapeutics stock:
  • 1. According to Zacks Investment Research, "Mirati Therapeutics, Inc. is a biopharmaceutical company. It engaged in the development of novel therapeutics for the treatment of cancer. Mirati Therapeutics, Inc., formerly known as MethylGene Inc., is based in Montreal, Canada. " (5/9/2018)
  • 2. Cann analysts commented, "Mirati Therapeutics, Inc. announced today that it has entered into an exclusive license agreement with BeiGene for the development, manufacturing and commercialization of Mirati’s sitravatinib in Asia (excluding Japan), Australia, and New Zealand. Mirati confirmed it will retain exclusive rights for the development, manufacturing and commercialization of sitravatinib for the rest of world." (1/8/2018)

Who are some of Mirati Therapeutics' key competitors?

Who are Mirati Therapeutics' key executives?

Mirati Therapeutics' management team includes the folowing people:
  • Dr. Rodney W. Lappe, Exec. Chairman (Age 63)
  • Dr. Charles M. Baum, Pres, CEO & Director (Age 60)
  • Dr. James Christensen, Sr. VP & Chief Scientific Officer (Age 50)
  • Dr. Isan Chen, Exec. VP and Chief Medical & Devel. Officer (Age 56)
  • Mr. Jamie A. Donadio, Sr. VP & CFO (Age 43)

Has Mirati Therapeutics been receiving favorable news coverage?

Media coverage about MRTX stock has trended somewhat positive on Saturday, Accern Sentiment Analysis reports. The research group rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Mirati Therapeutics earned a coverage optimism score of 0.04 on Accern's scale. They also gave media coverage about the biotechnology company an impact score of 46.93 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Who are Mirati Therapeutics' major shareholders?

Mirati Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Fred Alger Management Inc. (0.03%). Company insiders that own Mirati Therapeutics stock include Boxer Capital, Llc, Jamie A Donadio, Jamie Christensen, Ltd Braslyn, Tuesday Thirteen Inc and Venbio Select Advisor Llc. View Institutional Ownership Trends for Mirati Therapeutics.

Which institutional investors are buying Mirati Therapeutics stock?

MRTX stock was purchased by a variety of institutional investors in the last quarter, including Fred Alger Management Inc.. Company insiders that have bought Mirati Therapeutics stock in the last two years include Boxer Capital, Llc, Ltd Braslyn and Venbio Select Advisor Llc. View Insider Buying and Selling for Mirati Therapeutics.

How do I buy shares of Mirati Therapeutics?

Shares of MRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mirati Therapeutics' stock price today?

One share of MRTX stock can currently be purchased for approximately $55.05.

How big of a company is Mirati Therapeutics?

Mirati Therapeutics has a market capitalization of $1.48 billion. The biotechnology company earns $-70,420,000.00 in net income (profit) each year or ($2.78) on an earnings per share basis. Mirati Therapeutics employs 51 workers across the globe.

How can I contact Mirati Therapeutics?

Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-332-3410 or via email at [email protected]


MarketBeat Community Rating for Mirati Therapeutics (NASDAQ MRTX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  254 (Vote Outperform)
Underperform Votes:  185 (Vote Underperform)
Total Votes:  439
MarketBeat's community ratings are surveys of what our community members think about Mirati Therapeutics and other stocks. Vote "Outperform" if you believe MRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.